US Capital Chosen As Advisor On A Large Capital Raise By A Company Behind Silver-Cannabinoid Formula Against Drug-Resistant Infections

US Capital has been engaged by Andira Pharmaceuticals as its strategic advisor on a multi-million dollar capital raise round. Andira is a privately held woman-led health science company, developing therapeutics including its Matrix3 anti-infective technology for wound care, which has the potential to deliver protection against dangerous, drug-resistant bacterial infections.

The company is also developing injectable therapy for hospital acquired infections such as VRE and MRSA, as well as new treatments for breast cancer, with a focus on topical therapies for metastatic breast cancer and associated pain.

Headquartered in San Francisco with principal offices in Las Vegas, London, Milan, and Dubai, US Capital is a full-service global private financial group with an established track record in corporate finance, asset management, and capital formation services. All securities are offered by the group through its FINRA-member, SEC-registered broker-dealer affiliate, US Capital Global Securities LLC.

“An estimated 2.5% of the US population has suffered from chronic wounds in 2021, a problem seriously compounded by antibiotic resistance,” stated Andira’s president and CEO, Dr. Dana Lambert, who received her Ph.D. in Pharmaceutical Sciences from the University of British Columbia, Vancouver. “Currently, consumers do not have access to convenient, all-in-one products that offer protection against these dangerous infections. Andira’s Matrix3 is a triple synergy, patent-pending silver-cannabinoid formula that fills this important gap, providing three-day protection against multi-drug resistant infections, including MRSA and Pseudomonas.”

Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.

Photo by Tim Foster on Unsplash